In line with the above, the most recent National Comprehensive Cancer Network (NCCN) guidelines include HER2 IHC testing (with reflex to HER2 fluorescence in situ hybridization [FISH] for the equivocal IHC results) to be recommended for all serous and carcinosarcoma tumors. The gene discussed is ERBB2; the disease is carcinosarcoma.